Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s innovative pipeline of personalised cancer therapies….

CAR-T therapies have proven to be revolutionary treatments for cancer, but their high costs have limited patient access. The Australian Federal Government have addressed this…

Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news. Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company…

Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple cancer programs, with work to follow on from…

ASX-listed oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in developing a robust drug pipeline comprising CAR-T and targeted therapies (PTX-100 & PTX-200) for various…

Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has announced its June 2021 results, marked by impressive progress in its cancer programs and a robust financial…

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter. The clinical-stage oncology company focussed on driving multiple cancer programs for its…

In an update that endorses the potential benefits of Prescient Therapeutic’s (ASX:PTX) anti-cancer drug PTX-100, the Company stated that the first-in-class compound demonstrated an excellent…

Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an early clinical trial – and seemed to benefit two patients…

Australian biotech company Prescient Therapeutics has successfully finished a round of safety testing on its PTX-100 drug in a basket trial of patients with solid…